Effects of standard and low dose 17beta-estradiol plus norethisterone acetate on body composition and leptin in postmenopausal women at risk of body mass index and waist girth related cardiovascular and metabolic disease.
To compare the effects of standard and low dose of 17beta-estradiol/norethisterone acetate (E2/NETA) on body composition and leptin in postmenopausal women at risk of body mass index (BMI) -and waist girth (WG) related cardiovascular and metabolic disease. Ninety postmenopausal women aged 45-55 years with BMI >or= 25 kg/m2 participated in this 6-month prospective, randomized, single-blinded and controlled study, conducted between September 2004 and April 2006 at Adnan Menderes University Hospital. According to their WG, the subjects were divided into 2 risk groups: WG <88 cm (Group increased risk [IR], n=48) or WG >or= 88 cm (Group high risk [HR], n=42). The subjects in each group were equally assigned to receive standard or low dose of E2/NETA (2 mg E2/1 mg NETA, or 1 mg E2/0.5 mg NETA). Accordingly, the 2 groups were divided into 4 subgroups. Serum leptin levels (SLLs), body weight/height, waist/hip girth, BMI and waist-to-hip ratio were evaluated before and after therapy. In the Group IR, WG decreased significantly only in low dose subgroup. In the Group HR, both standard and low dose subgroups had a significant reduction in WG. Those who had WG >or= 88 cm showed more reduction than those who had WG <88 cm in response to both doses of E2/NETA, insignificantly. Basal SLLs had a significant correlation with body weight, BMI and WG. Oral standard and low dose E2/NETA reduce WG and attenuate the BMI- and waist girth- related risk of cardiovascular and metabolic diseases in postmenopausal women.